Heart docs pan Vytorin

Share this article:

Vytorin and Zetia risk being relegated to second- or third-line therapies after taking a drubbing at last weekend's annual meeting of the American College of Cardiology.

Merck and Schering-Plough had pinned their hopes for a turnaround in perceptions of the drug on the conference, where they felt a reasoned discussion of the full results of the Enhance trial might mitigate the damage done. But analysts and attendees saw little of note that was new in the full results, published in the New England Journal of Medicine, and panelists slammed the combo drug.

Saturday featured a discussion of the Enhance results by Cleveland Clinic's Dr. Steven Nissen and Duke's Dr. Robert Califf. “The Saturday discussion by Nissen was expected,” wrote Bernstein analyst Tim Anderson in a note, “negative on Vytorin, which was in line with his original position. Dr. Califf tried to offer at least some degree of balance, but Nissen stole the show.” A panel discussion on the results the following day “was a mess, to put it bluntly,” said Anderson, applying scare quotes to the term “panel.” “It was essentially not a panel discussion at all, but rather a monologue by Dr. Harlan Krumholz, who was very negative on Vytorin. The other panelists did not speak.”

To top it all off, the New England Journal of Medicine issued an editorial calling the results “a red flag but not a black box,” nonetheless urging physicians to first try statins plus niacin and fibrates, then try Zetia in patients for whom that doesn't work.

"We were surprised that the scientific forum that we were waiting for didn't occur," Schering-Plough CEO Fred Hassan told the Wall Street Journal, adding that "the panel was selected based on some credentials that we don't understand, and secondly, the way the panel proceeded was something that we would not call a scientific forum. ... It was basically a statement and basically there was no participation by the audience."

Hassan told the Journal that while Schering-Plough has no immediate plans for a shakeup in response to the drugs' travails, "If revenues are going to be permanently impaired, then we would need to size the company to line up with that size."

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...